# US 2006/0233840 A1 · Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0233840 A1
- Document ID: US20060233840A1
- Status: Published application
- Kind: A1
- Application number: 11/393,155
- Filed: 2006-03-29
- Published: 2006-10-19
- Earliest claimed: 1999-11-15
- Assignees: Miltenyi Biotech GmbH
- Inventors: Juergen Schmitz; Andrzej Dzionek; David Buck
- Web page: https://patentgrep.com/patent/US20060233840A1

## CPC

- C07K 14/7056: {Lectin superfamily, e.g. CD23, CD72}
- C07K 16/2851: {against the lectin superfamily, e.g. CD23, CD72}
- Y10S 435/81: Packaged device or kit
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

## Abstract

The invention provides antigen-binding fragments specific for dendritic cells and effective in treatment and/or diagnosing a variety of disorders. Methods of use are also provided as are methods for screening for additional such antigen-binding fragments and the products obtained thereby.

## Claims

### Claim at position 1

1-154. (canceled)

### Claim 155

A cell composition enriched for human dendritic cells that express BDCA-4 (neuropilin-1/CD304).

### Claim 156 (depends on 155)

The composition according to claim 155 comprising a physiologically acceptable excipient.

### Claim 157 (depends on 155)

The composition according to claim 155, wherein said dendritic cells present an antigenic peptide (T cell epitope) on the cell surface.

### Claim 158 (depends on 155)

The composition according to claim 155 wherein the antigenic peptide is expressed from an exogenously derived gene or mRNA.

### Claim 159 (depends on 155)

The composition according to claim 155 wherein the antigenic peptide is derived from an antigen that is an autoantigen, an allergen, or an antigen expressed by virally infected cells or cancer cells.

### Claim 160 (depends on 155)

The composition according to claim 155 wherein the dendritic cells have been matured in vitro.

### Claim 161 (depends on 155)

The composition according to claim 155 wherein at least 80% of the dendritic cells express BDCA-4 (neuropilin-1/CD304).

### Claim 162 (depends on 161)

The composition according to claim 161 where at least 90% of the dendritic cells express BDCA-4 (neuropilin-1/CD304).

### Claim 163

An ex vivo or in vitro dendritic cell labeled with an antibody that binds BDCA-4 (neuropilin-1/CD304), or antigen-binding fragment thereof, or an ex vivo or in vitro population of dendritic cells so labeled.

### Claim 164 (depends on 163)

The cell or population of claim 163, wherein the antibody is monoclonal.

### Claim 165 (depends on 163)

The cell or population of claim 163, wherein the antibody or antigen-binding fragment is conjugated to a detectable label or a paramagnetic label.

### Claim 166 (depends on 163)

The cell or population of claim 163, wherein the antibody or antigen-binding fragment is conjugated to a super-paramagnetic bead.

### Claim 167

A method for isolating or enriching for dendritic cells from a mixture of human cells:
a) obtaining a mixture of human cells;
b) contacting cells in the mixture with an antibody that binds BDCA-4 (neuropilin-1/CD304), or antigen-binding fragment thereof, under conditions in which the antibody or antigen-binding fragment labels BDCA-4+ dendritic cells; and
c) separating dendritic cells bound by the antibody or antigen-binding fragment from other cells in the mixture.

### Claim 168 (depends on 167)

The method of claim 167 wherein the dendritic cells are separated by immunomagnetic cell sorting (MACS).

### Claim 169 (depends on 167)

The method of claim 167 wherein the dendritic cells are separated by flow cytometry (FACS).

### Claim 170 (depends on 167)

The method of claim 167, wherein the mixture of human cells is obtained from bone marrow, from peripheral blood, or from cell culture.

### Claim 171 (depends on 167)

The method of claim 167 wherein the mixture of human cells is obtained by leukopheresis of peripheral blood.

### Claim 172 (depends on 167)

The method of claim 167 wherein the mixture of human cells is from a source selected from umbilical cord blood, tonsil, lymph node, nasal membrane, spleen, skin, airway epithelia, lung, liver, gut, spleen, lymph node, thymus, and Peyers patches.

### Claim 173 (depends on 167)

A composition comprising dendritic cells isolated according to claim 167.

### Claim 174 (depends on 155)

A method of generating a T cell and/or humoral immune response specific for an antigen comprising administering to a subject in need thereof an effective amount of a composition of claim 155.

### Claim 175

A method of modulating dendritic cell cytokine production comprising the steps of isolating a substantially pure population or subpopulation of dendritic cells based on binding of an antigen binding fragment specific for BDCA-4 (neuropilin-1/CD304); and treating the cells with an agent that modulates dendritic cell cytokine production.
